Murali Ramachandran
SEC insider (Form 3/4/5 filer). CIK 0001870016. VP of Research and Development at Kairos Pharma, LTD. (KAPA). 3 reported Form 4/5 transactions since Sep 2024; latest on Oct 8, 2025. Located in LOS ANGELES, CA.
Companies Murali Ramachandran has filed insider reports for
- Kairos Pharma, LTD. (KAPA): Officer, VP of Research and Development
Murali Ramachandran
CIK: 0001870016
Transaction Breakdown
Open Market Buys (P)1 (33.3%)
High conviction signal
Open Market Sales (S)0 (0.0%)
Position reduction
Option Exercises (M)0 (0.0%)
Derivative conversions
Awards (A)2 (66.7%)
Compensation grants
Other (G, F, J, C, D, …)0 (0.0%)
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
KAPA
Kairos Pharma, LTD.
Officer